CD274 and non-small cell lung carcinoma: According to the results of the abovementioned trials, PD-1 or PD-L1 blockade in second line treatment of NSCLC patients provides better survival and better safety profile than docetaxel, which allowed changing the standard of care for patients progressing after platinum-based first line therapy.